Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $140.00 short call and a strike $145.00 long call offers a potential 52.44% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $140.00 by expiration. The full premium credit of $1.72 would be kept by the premium seller. The risk of $3.28 would be incurred if the stock rose above the $145.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 68.62 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
Mon, 27 Jan 2020 22:34:00 +0000
The U.S. Food and Drug Administration (FDA) has approved Trijardy™ XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy XR provides three type 2 diabetes medicines in one pill, including Jardiance® (empagliflozin), Tradjenta® (linagliptin) and metformin hydrochloride extended release. Trijardy XR is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY).
Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap
Mon, 27 Jan 2020 16:59:00 +0000
Eli Lilly is in a potential buy area with its next quarterly report on tap for sometime near Jan. 30.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
Mon, 27 Jan 2020 16:30:04 +0000
Is (LLY) Outperforming Other Medical Stocks This Year?
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
Mon, 27 Jan 2020 13:16:01 +0000
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Mon, 27 Jan 2020 11:45:00 +0000
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib in combination with topical corticosteroids (TCS) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine. The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.
Also on Market Tamer…
Follow Us on Facebook